Table 1.

Cdk5 activity in donor T cells is primarily responsible for reductions in GVHD

GroupGVHD scoreSurvival, %
Week 4Week 5Week 6
F1 → F10.2 ± 0.20.0 ± 0.00.0 ± 0.0100
Allo WT T + Allo WT BM → F15.0 ± 0.45.2 ± 0.55.8 ± 0.113
Allo WT T + Allo KO BM → F14.8 ± 0.64.6 ± 0.64.5 ± 0.533
Allo KO T + Allo KO BM → F12.4 ± 0.3*2.5 ± 0.4*3.0 ± 0.5*73*
Allo KO T + Allo WT BM → F13.2 ± 0.8*2.6 ± 0.5*2.7 ± 0.4*60*
  • Lethally irradiated B6D2F1 received HCT from either syngeneic B6D2F1 or allogeneic Cdk5+/+C (Allo WT) or Cdk5−/−C (Allo KO) donors as described in Figure 2. Two additional allogeneic groups were evaluated in this “mixing” experiment as described in “Methods”: allogeneic KO BM cells mixed with allogeneic WT T cells and allogeneic WT BM cells mixed with allogeneic KO T cells. Survival was monitored daily and GVHD clinical scores were assessed weekly as described; n = 8 to 16 per group.

  • * P < .01 compared with recipients of Cdk5+/+C HCT.